Aurinia Pharmaceuticals (AUP) Stock Price, News & Analysis

Company Overview

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 4.61 million shs
• Average Volume: 229,895 shs
• Market Capitalization: C$2.15 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: TSE:AUP
• Previous Symbol: TSE:ISA
• CIK: N/A
• Web: www.auriniapharma.com
• Phone: +1-250-7084272
• Fax: N/A
• Employees: 300
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 2.69
• Current Ratio: 11.93
• Quick Ratio: 11.02

Sales & Book Value

• Annual Sales: C$57.59 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 6.75
• Book Value: C$2.59 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 128,396,000
• Free Float: N/A
• Market Cap: C$2.15 billion
• Optionable: Not Optionable
• Beta: N/A